Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2011. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific transaction notification and does not contain comprehensive financial statements.
Material Changes
No material changes to the company's financial position or operations are reported in this document. The filing details a specific administrative adjustment within a retirement plan rather than a change in corporate performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It strictly reports a transaction notified under Disclosure and Transparency Rule 3.1.4R(1)(c).
Important Facts for Investors
- Transaction Type: Re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan.
- Involved Parties: Dr. M M Slaoui (Director/PDMR) and Dr. K Slaoui (Connected Person).
- Transaction Details: An increase in the notional allocation of 4 Ordinary share ADRs occurred on April 15, 2011.
- Price: The transaction was recorded at a price of $41.13 per ADR.
- Notification Date: The company was notified of this transaction on April 19, 2011.